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Introduction
IFNg is the pivotal mediator in murine models of
primary HLH.
Objectives
Given the similarities between primary and secondary
(sHLH), including MAS, we analyzed IFNg levels in
patients with sJIA and MAS and evaluated the pathogenic
role of IFNg in a murine MAS model.
Methods
We measured levels of IFNg, IFNg-related chemokines
(CXCL9, CXCL10, CXCL11), and IL-6 in patients with
sHLH (n=14), and in patients with sJIA (n=54) of whom
20 had MAS at sampling using the Luminex multiplex-
ing assay and evaluated their relation to disease activity.
The effect of the anti-IFNg antibody XMG1.2 was
assessed in IL-6 transgenic (IL6TG) mice in which a
MAS-like syndrome leading to death is triggered by
TLR ligands (Strippoli, Arthritis Rheum 2012). An LPS
LD50 (5 μg/gr body weight) was used, as a trigger for
MAS, followed 10 hours later by administration of
100 μg/gr of XMG1.2.
Results
Levels of IFNg and of IFNg-related chemokines [median
pg/ml(IQR)] were markedly elevated in active MAS and
active sHLH, with no significant differences between
active sHLH [IFNg 34.7(23.9-170.1); CXCL9 33598
(3083-127687); CXCL10 4420(799.7-8226); CXCL11
1327(189-2000)] and active MAS [IFNg 15.4(5.1-52.6);
CXCL9 13392(2163-35452); CXCL10 1612(424.8-4309);
CXCL11 564.8(197.5-1007)]. Levels in active sJIA with-
out MAS at sampling [IFNg 4.88(3.2-8.7); CXCL9 836.5
(470.9-2505); CXCL10 307.3(198.9-693.7); CXCL11
121.7(62-197.1)] were lower (all p-values <0.01) than in
active sHLH or active MAS. IL-6 was not different
between the three groups. In active MAS, platelet count
was inversely related to IFNg (r=-0.53; p=0.02), CXCL9
(r=-0.51; p=0.03) and CXCL10 (r=-0.58; p=0.009). In the
murine MAS model, treatment with the anti-IFNg anti-
body XMG1.2 resulted in increased survival (XMG1.2-
treated 10 survivors/10 treated; control-treated 5/10;
p=0.033).
Conclusion
IFNg, and IFNg-related chemokine levels were increased in
patients with MAS compared to patients with active sJIA
without MAS, and associated with low platelet count.
Neutralization of IFNg increased survival in murine MAS.
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